[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligometastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligometastasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,77,118,143,168,194,217,242,270,302,341,364,393,431,456],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624737","randomized-trial-of-standard-of-care-with-or-without-metastases-directed-stereotactic-body-radiation-therapy-in-patients-affected-by-oligometastatic-urothelial-carcinoma-100624737",false,"NCT07413523","Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA","Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA: ASTRA Trial","ASTRA","Inclusion Criteria:\n\n* Age \\> 18 years\n* WHO performance status ≤ 2\n* Pathological proven urothelial carcinoma\n* Stage IV disease at imaging\n* Maximum of 3 extracranial metastases\n* Indication to receive I or II line of standard systemic therapy\n* Adequate liver function\n* Adequate bone marrow function\n* Written informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Previous radiation therapy on the same target lesions\n* Pregnant or breastfeeding patients\n* Prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ carcinoma of the cervix, surgically cured, or localized prostate cancer without evidence of biochemical progression)\n* Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study\n* WHO PS \\>=3","ALL","18 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"NA","Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options available.\n\nAt the moment, standard treatment mainly includes systemic therapies, such as chemotherapy and immunotherapy (immune checkpoint inhibitors). These treatments act on the whole body. However, the use of local treatments, such as stereotactic radiotherapy, has not been well studied in bladder cancer.\n\nStereotactic radiotherapy is a type of radiation treatment that delivers very high doses of radiation to the tumor in a small number of treatment sessions. This technique is already widely used to treat a limited number of metastases (called oligometastases) from other types of cancer.\n\nThe aim of this study is to understand whether stereotactic radiotherapy is also effective and safe for treating oligometastases coming from bladder cancer.",[27,28,29],"Bladder Cancer","Urothelial Carcinoma (UC)","Oligometastasis",[31,32,33,34,35,36],"SBRT","SYSTEMIC TREATMENT","UROTHELIAL CARCINOMA","BLADDER CANCER","OLIGOMETASTASIS","RADIOTHERAPY","RECRUITING","2026-04-24",{"date":40,"type":41},"2026-04-30","ACTUAL",{"date":43,"type":41},"2026-02-16",{"date":45,"type":21},"2030-02",{"name":47,"class":48},"Istituto Clinico Humanitas","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100298169","phase-2-chemotherapy-with-or-without-radiation-or-surgery-in-treating-participants-with-oligometastatic-esophageal-or-gastric-cancer-100298169","NCT03161522","Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer","A Randomized Trial Comparing Early Local Chemoradiation Therapy +\u002F- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With Oligometastases","Inclusion Criteria:\n\n* The patient has a pathologic diagnosis of tumor biopsy or FNA of esophageal or gastric cancer of adenocarcinoma histology\n* The patient is staged with EGD and PET\u002FCT scan.\n* The patient has three or less observable metastatic lesions. Patients may have three or less radiographically visible metastatic lesions at diagnosis or if have regressed to three or less metastatic lesions after induction chemotherapy at time of randomization. The patient must have pathologic confirmation and or radiologically visible disease. For esophageal tumors, the maximal dimension of the primary tumor may not provide reproducible measurements for RECIST and may not be visible on CT or PET\u002FCT at diagnosis or after induction chemotherapy. Accordingly, patients are eligible regardless of the imaging measurements of the primary tumor. Additionally, in patients with non-measurable metastases, patients are eligible if there is pathology confirming metastases from a distant site. However, biopsy of a metastatic site is not required if there are visible metastases on imaging (such as ultrasound, diagnostic CT , EUS, PET\u002FCT).\n\n  * The patient has three or less observable metastatic lesions by diagnostic scans (CT scan, PET\u002FCT, eEndoscopic ultrasound, MRI, or bone scan). Metastatic lesions include distant M1 lymph node group; which will be counted as one site (M1 metastatic lymph nodes to include cervical, mediastinal, gastric, retroperitoneal lymph nodes will be counted as one lesion).\n  * Osseous metastases or visceral metastases will each count as one metastatic site.\n  * Each CNS metastases will count as one metastatic site.\n  * Satellite lesions in the primary esophageal malignancy such as skipped esophageal primaries are not considered metastatic sites. Symptomatic metastatic sites can be treated locally prior to randomization or by palliative radiation.\n  * Symptomatic metastatic sites may be treated with radiation or surgery prior to enrollment.\n* Patient ECOG of 0-2, with life expectancy of at least 6 months\n* Patients age \\>18 yrs old but \\\u003C80 yrs old and signed informed consent\n* Women of child-bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents.\n\nExclusion Criteria:\n\n* Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized.\n* Patients with fistula documented radiographically or by EDG\u002FEUS, EBUS.\n* Patients with life expectancy less than 6 months, ECOG \\>3\n* Female patients who are pregnant confirmed by bHCG lab test.\n* Patient has history of uncontrolled angina, congestive heart failure or recent MI within 6 months.\n* Nursing females\n* Patients in poor nutritional state\n* Patients with:\n\n  * Severely depressed bone marrow function\n  * Potentially serious infections\n  * Known hypersensitivity to 5-fluorouracil\n  * Known or suspected to have a dihydropyrimidine dehydrogenase deficiency (as these patients are at a greater risk of experiencing symptoms of toxicity)","79 Years",{"count":59,"type":21},100,[61],"PHASE2","This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.",[64,29,65,66,67],"Gastric Adenocarcinoma","Stage IV Esophageal Adenocarcinoma AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","2026-04-10",{"date":70,"type":41},"2026-04-15",{"date":72,"type":41},"2018-02-19",{"date":74,"type":21},"2026-12-31",{"name":76,"class":48},"M.D. Anderson Cancer Center",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":97,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100422969","phase-2-veterans-affairs-seamless-phase-iiiii-randomized-trial-of-standard-systemic-therapy-with-or-without-pet-directed-local-therapy-for-oligometastatic-prostate-cancer-100422969","NCT04787744","Veterans Affairs Seamless Phase II\u002FIII Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","Veterans Affairs Seamless Phase II\u002FIII Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)","VA STARPORT","Inclusion Criteria:\n\nAge 18 years. Ability to provide Informed Consent for participation in the study ECOG Performance Status 2 at time of enrollment. Prostate cancer, confirmed histologically or cytologically. If original documentation of histology and cytology are not available, documentation of prostate cancer satisfies these criteria. If recurrent, prior curative-intent local therapy to all sites of prostate cancer with either upfront radiotherapy or prostatectomy with or without post-operative radiotherapy.\n\nIf recurrent, PSA suspicious for biochemical recurrence after local therapy, with lab value(s) taken prior to start of SST (if current SST has already started) or within 90 days prior to enrollment if not already on SST, and meeting one of the three below categories:\n\nPSA 0.2 ng\u002Fml x 2 after prostatectomy +\u002F- post-operative radiotherapy; Elevation of PSA 2 ng\u002Fml above the nadir after definitive radiotherapy; Or Two consecutively elevated PSAs with evidence of metastasis on the imaging Studies.\n\n-Serum testosterone obtained prior to randomization based on one of the criteria below:\n\nFor patients who have a history of a prior episode of therapy with SST agents for prostate cancer, a total testosterone 100 ng\u002Fdl after completion of the prior episode of SST and before the start of current SST or within 30 days of starting current SST if the patient has already started SST for recurrence.\n\nFor patients who have no prior history of an episode of therapy with SST agents and have already started SST for recurrence, this pre-SST testosterone is not required.\n\nCT or MRI abdomen\u002Fpelvis performed prior to start of SST (if current SST has already started) or within 90 days prior to enrollment if not already on SST. The results from the CT component of the PET\u002FCT can be used to fulfill this criterion. This is optional for patients who have a PSMA PET\u002FCT. Yechnetium (Tc99m-MDP) or sodium fluoride (NaF) bone scan (sodium fluoride preferred) performed prior to start of SST (if current SST has already started), or within 90 days prior to enrollment if not already on SST. This is optional for patients who have a PSMA PET\u002FCT. Prostate PET\u002FCT (currently PSMA, Fluciclovine, choline) performed prior to start of SST (if current SST has already started), or within 90 days prior to enrollment if not already on SST.\n\n1-10 lesions suspicious for nodal recurrence or metastasis from prostate cancer as determined by the investigator based on the above imaging studies.\n\nHas already undergone NPOP sequencing or a plan is in place for NPOP sequencing for prostate cancer.\n\nFor participants on SST at the time of enrollment only:\n\nHas been on SST for 180 days. For participants with local recurrence after curative-intent local therapy on imaging :\n\nPatients with local recurrence in the prostate, SV, or prostate bed are eligible as long as there is at least 1 nodal or distant metastatic recurrence. Biopsy must confirm local recurrence for patients who have had prior curative-intent radiation to the prostate, SV, or prostate bed.\n\nCandidate for salvage local therapy (refer to Section 10.4) as determined by a urologist or radiation oncologist (depending on the respective modality to be used to treat the local recurrence).\n\nFor participants with de novo prostate cancer:\n\nCandidate for prostate-directed radiation.\n\nExclusion Criteria:\n\n* Any current or prior evidence of castration-resistant prostate cancer, defined as two consecutive rises in serum PSA, obtained at a minimum of 1-week interval, with the final PSA value \\>\u002F= 1 ng\u002Fml, while having a total testosterone \\\u003C 50 ng\u002Fdl).\n* Prior malignancy, except the following:\n\n  * Adequately treated non-melanomatous skin cancer;\n  * Adequately treated Stage 0, I, or II cancer from which the patient is currently in complete remission; or\n  * Any other cancer from which the patient has been disease free for three years.\n* Presence of a symptomatic metastasis that requires palliative radiotherapy.\n* Any known brain metastases, presence of leptomeningeal disease, malignant spinal cord compression, or malignant cauda equina syndrome.\n* Prior nodal, bone, or visceral metastasis after curative-intent therapy other than those identified on the enrollment imaging studies which make the patient ineligible for PET-directed local therapy (per investigator discretion).\n* Prior radiation therapy to any sites requiring PET-directed local therapy or salvage local therapy that will lead to prohibitively high risk of toxicity from subsequent local therapy, as determined by the treating radiation oncologist (if radiation is intended as the study local therapy) or surgeon\u002Furologist (if surgery is intended as the study local therapy).\n* Any other previous or current condition, which, in the judgement of the LSI, is likely to interfere with any STARPORT treatments or assessments.","MALE",{"count":87,"type":21},464,[61,89],"PHASE3","This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.",[92,29,93,94,95,96],"Prostate Cancer","Oligorecurrence","Recurrent Prostate Cancer","Metastatic Prostate Cancer","De Novo Prostate Cancer",[92,98,93,99,100,31,29,101,102,103,94,104,105,106],"Metastasis","PET-directed local therapy","Standard Systemic Therapy","Oligorecurrent","Metastasis-directed therapy","Salvage Local Therapy","Fluciclovine","PSMA","Choline","2026-04-02",{"date":109,"type":41},"2026-04-08",{"date":111,"type":41},"2021-07-01",{"date":113,"type":21},"2029-03-30",{"name":115,"class":116},"VA Office of Research and Development","FED",20,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":49},"100599023","phase-1-trial-of-oligometastasis-sbrt-with-immediate-simulation-free-treatment-delivery-oligo-swift-100599023","NCT07079098","Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)","Pilot\u002FPhase I Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)","Inclusion Criteria:\n\n* Participants must have histologically, cytologically, or radiographically or confirmed cancer that is oligometastastatic (defined in this protocol as up to 5 active sites of disease at time of trial enrollment). Note that previous ablative therapy to the treatment site (excluding prior external beam radiation) is permitted, such as previous microwave ablation or radiofrequency ablation.\n* Age ≥18 years.\n* Performance status: Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2\n* Estimated life expectancy of at least 3 months\n* Participants must be considered a candidate for SBRT by the treating physician\n* Prior chemotherapy or biological treatment is allowed, but any active oncological treatment should be stopped at least 1 week prior to radiation therapy and renewed no sooner than 1 week following radiation therapy, with the exception of endocrine therapies, which can continue through radiation treatment.\n* Participants must have the ability to understand and the willingness to sign a written informed consent document.\n* Participants must have a diagnostic CT, MRI, or PET\u002FCT of the site(s) intended for treatment, with or without contrast, acquired no more than 30 days prior to study consent.\n\nExclusion Criteria:\n\n* Prior radiotherapy to any site overlapping with the projected site for protocol treatment.\n* Participants with isolated vertebral metastases except for sacral spine; participants with osseous spine disease can be treated upon this protocol, but those sites (cervical, thoracic, lumbar spine) are not permitted for treatment upon this study. Such participants could be enrolled for treatment to other, concurrent (e.g., visceral, or non-spine bone) disease on this study.\n* Pregnant or breastfeeding women are excluded from this study.\n* Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by the treating physician or protocol principal investigator (PI), documentation of this exception is sufficient in lieu of a pregnancy test.",{"count":126,"type":21},15,[128],"PHASE1","This study is for participants whose cancer is oligometastatic, meaning it has spread to up to five spots in their body and their doctor recommends that they have stereotactic body radiation therapy (SBRT) to treat these cancer sites. SBRT is a type of radiation therapy that may help people with oligometastatic disease live longer without cancer progression. SBRT is usually given in addition to other cancer treatments, like chemotherapy, immunotherapy, or hormone therapy.\n\nPreparing for SBRT can take up to a week or longer. This can make it harder for participants to receive SBRT and coordinate care. This can also mean a longer time until symptoms from cancer sites improve. Doctors would like to treat oligometastatic cancers more quickly by reducing the time it takes to plan for the SBRT.\n\nThe typical workflow for SBRT includes doctors doing a simulation which requires a CT (Computerized Tomography) scan. The CT scan is used to create a treatment plan. It can take time to schedule this CT scan and then it normally takes another 5-10 days to create a treatment plan.\n\nA way to reduce the planning time for SBRT is to use the CT scan (or other radiology scan types, like magnetic resonance imaging \\[MRI\\] or positron emission tomography \\[PET\\]) that participants had when their cancer was diagnosed to plan their SBRT. This eliminates the scheduling of an additional CT scan and the 5-10 day planning time. This is called CTsim-free (CT simulation-free) treatment planning.\n\nCT-sim-free radiation therapy planning has been shown to be effective in treating cancers that are causing pain in people with more advanced or widespread cancers. This study is being done to find out if it is safe and effective to use CTsim-free planning for SBRT to treat oligometastases.",[29,131],"Oligometastatic Disease",[133,31],"Stereotactic Body Radiation Therapy","2026-03-02",{"date":136,"type":41},"2026-03-03",{"date":138,"type":41},"2026-02-27",{"date":140,"type":21},"2027-02",{"name":142,"class":48},"Case Comprehensive Cancer Center",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":167},"100623511","stereotactic-body-radiotherapy-for-extracranial-oligometastatic-breast-cancer-multi-institutional-retrospective-database-100623511","NCT07397585","stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database","ORIETTA","Inclusion Criteria:\n\n* Patients ≥18 years\n* Histological diagnosis of breast cancer\n* Oligometastatic or oligoprogressive metastatic breast cancer\n* SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition\n* Ability to provide written informed consent",{"count":151,"type":21},300,"OBSERVATIONAL","Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.",[155,29],"Breast Cancer",[157,158,159,31],"breast cancer","oligometastasis","radiotherapy","2026-02-09",{"date":162,"type":41},"2026-02-11",{"date":164,"type":41},"2025-02-25",{"date":74,"type":21},{"name":47,"class":48},28,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":49},"100526513","phase-3-metastasis-directed-therapy-for-oligometastases-of-breast-cancer-100526513","NCT06135714","Metastasis-directed Therapy for Oligometastases of Breast Cancer","a Randomized Trial for OLIGo Metastases Breast cAncer With or Without Metastasis-dIrected Therapy","OLIGAMI","Primary Registration Eligibility Criteria:\n\n1. Histologically diagnosed as invasive breast cancer. Biopsy from oligometastasis is desirable but not required.\n2. Histologically proven positive\u002Fnegative for ER, PgR, and HER2, and classified as luminal, HER2-positive, or TN breast cancer.\n3. One of the following \\\u003C1\\> to \\\u003C4\\>; \\\u003C1\\>In case of no history of breast cancer in the past, either (i) or (ii) below.\n\n   (i) Unilateral noninvasive breast cancer at registration, diagnosed as invasive breast cancer by biopsy from oligometastasis (ii) Unilateral invasive breast cancer at registration \\\u003C2\\>In case of having a history of mastectomy or breast-conserving surgery for unilateral noninvasive breast cancer, either (i) or (ii) below. (i) Absence of breast\u002Fchest wall tumor at registration and diagnosed as invasive breast cancer by biopsy from oligometastasis (ii) Unilateral invasive breast cancer at registration (whether ipsilateral or contralateral to previous breast cancer) \\\u003C3\\>In case of having a history of mastectomy or breast-conserving surgery for unilateral invasive breast cancer, either (i) or (ii) below. (i) Absence of breast\u002Fchest wall tumor at registration (ii) Ipsilateral invasive\u002Fnoninvasive breast cancer to previous breast cancer at registration and diagnosed as recurrence \\\u003C4\\>In case of having a history of mastectomy or breast-conserving surgery for unilateral noninvasive breast cancer and contralateral invasive breast cancer, no breast\u002Fchest wall tumor at registration.\n4. Diagnosed with advanced breast cancer with oligometastasis by neck to pelvis enhanced CT, FDG-PET (PET\u002FCT), and brain enhanced MRI.\n5. oligometastasis defined as: (i) Maximum diameter of each tumor is 3 cm or less (ii) Total number of 3 or less. (iii) In case of brain metastasis, maximum diameter is 2 cm or less and asymptomatic.\n6. No distant metastasis other than oligometastasis.\n7. Metastasis-directed therapy (radiation or surgery) is considered feasible for all oligometastases.\n8. In case of bone metastasis, none of the following:\n\n   (i) Metastasis of three consecutive vertebral bodies (ii) Spinal metastasis extending into the spinal canal (Bilsky grade is 1b or higher) (iii) Long bone metastasis extending to the femoral head, neck, and trochanter (iv) Long bone metastasis with more than 1\u002F3 of bone cortical defects (v) Severe pain uncontrolled with drugs.\n9. Aged 18-80 years.\n10. ECOG performance status of 0 or 1.\n11. A measurable lesion is not required.\n12. No history of surgery, drug therapy, or radiotherapy for distant metastasis. Bisphosphonate preparations and RANKL inhibitors before registration, and surgery for the purpose of diagnosing metastasis are permitted.\n13. No radical surgery of the primary tumor or regional lymph nodes between diagnosis of oligometastasis to registration.\n14. In the case of recurrent breast cancer, disease-free interval of 12 months or more from surgery, perioperative chemotherapy, or molecular targeted therapy for initial treatment of breast cancer.\n15. No prior treatment of endocrine therapy, chemotherapy, molecular targeted therapy, and immunotherapy against any other malignancies within 5 years.\n16. Adequate organ function within 14 days prior to the first registration. (i) ANC \\>= 1500 cells\u002Fmm3 (ii) Hemoglobin \\>= 9.0 g\u002FdL (iii) Platelet count \\>= 100,000\u002F mm3 (iv) Serum bilirubin \\\u003C= 1.5 mg\u002FdL (v) AST \\\u003C= 100 U\u002FL (vi) ALT \\\u003C= 100 U\u002FL (vii) Creatinine \\\u003C= 1.5 mg\u002FdL (\\\u003C= 2.3 mg\u002FdL for luminal breast cancer)\n17. Ejection fraction of cardiac function is defined over 50%.\n18. Written informed consent.\n\nSecondary Registration Eligibility Criteria:\n\n1. Primary registration in this study, and the planned number of courses of systemic drug therapy by subtype has been performed.\n2. No progression or new distant metastasis by response evaluation.\n3. Secondary registration is within 28 days from response evaluation.\n4. Within 84-126 days from the primary registration.\n5. At least one oligometastasis remains on imaging and considered feasible to definitive local therapy.\n6. No metastasis-directed therapy for breast cancer after primary registration.\n7. ECOG performance status of 0 or 1.\n8. Adequate organ function within 14 days prior to the second registration. (i) ANC \\>= 1500 cells\u002Fmm3 (ii) Hemoglobin \\>= 9.0 g\u002FdL (iii) Platelet count \\>= 100,000\u002F mm3 (iv) Serum bilirubin \\\u003C= 1.5 mg\u002FdL (v) AST \\\u003C= 100 U\u002FL (vi) ALT \\\u003C= 100 U\u002FL (vii) Creatinine \\\u003C= 1.5 mg\u002FdL (\\\u003C= 2.3 mg\u002FdL for luminal breast cancer)\n\nExclusion Criteria:\n\n1. Active malignancies curatively treated with no evidence of disease for \\>= 5 years prior to randomization.\n2. Infection with care.\n3. Fever up 38 degrees Celsius.\n4. Childbearing potential, delivery after 28 days, breastfeeding\n5. Mental disorders.\n6. Continuously take steroids or immunosuppressive drugs.\n7. Unstable angina or history of cardiac infarction within 6months.\n8. Uncontrolled Hypertension.\n9. Uncontrolled Diabetes mellitus.\n10. Congestive heart failure deserved class II of New York Heart Association (NYHA), uncontrolled Dilated or Hypertrophic cardiomyopathy.\n11. Severe arrhythmia need to cure (except Atrial fibrillation, Paroxysmal supraventricular tachycardia)\n12. Interstitial pneumonia, pulmonary fibrosis, severe emphysema diagnosed chest CT scan.\n13. HBs Ag+","80 Years",{"count":178,"type":21},340,[89],"OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group. After the first registration, all patients will be performed in a 12-week, subtype-specific, systemic therapy consisting of CDK4\u002F6 inhibitors with hormonal therapy for luminal BC, docetaxel with trastuzumab and pertuzumab for HER2-positive BC, chemotherapy with immune checkpoint inhibitors for triple-negativeBC expressing PD-L1, and olaparib for cases harboring BRCA mutations. For other triple-negative BC, chemotherapy will be administered. If this 12-week systemic therapy does not cause any progression or complete response, patients proceed to second registration for randomization; arm A continues same systemic therapy alone, and arm B performs MDT followed by same systemic therapy. The MDT will involve either RT or surgery, and RT will involve mainly SBRT and partly conventional RT.",[155,29,182],"Metastatic Breast Cancer",[31,184,133,185],"Surgery","Metastasis-directed Therapy","2026-02-08",{"date":162,"type":41},{"date":189,"type":41},"2023-11-08",{"date":191,"type":21},"2032-10-31",{"name":193,"class":48},"Tokyo Medical and Dental University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":201,"studyType":152,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100369031","role-of-ablative-radiotherapy-in-the-management-of-metastatic-disease-a-patient-data-registry-100369031","NCT04085029","Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment\n* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)\n* Patient must sign study-specific informed consent\n\nExclusion Criteria:\n\n• None",{"count":151,"type":21},"10 Years","The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.",[29,204],"Metastatic Cancer",[206],"Ablative radiotherapy","2026-02-03",{"date":209,"type":41},"2026-02-05",{"date":211,"type":41},"2019-09-26",{"date":213,"type":21},"2029-09",{"name":215,"class":48},"Duke University",5,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":225,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":49},"100559381","phase-3-stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial-100559381","NCT06563388","Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial","(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary","ID-COMET","Inclusion Criteria:\n\n* Age 1 year or older.\n* Willing to provide informed consent.\n* ECOG ≤ 3.\n* Life expectancy \\> 6 months.\n* Trials 1-3: Histologically confirmed lung, prostate or colorectal malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Trial 4: Any malignancy with metastasis. Participants with liquid tumors are eligible provided they have biopsy confirmed refractory disease and are eligible for salvage radiotherapy.\n* Newly diagnosed metastatic (1-10 sites)patients for Trials 1-3. Previously diagnosed metastatic patients (1-10 sites or oligoprogression in 5 or fewer sites with no limit on total number for Trial 4.\n* Restaging completed within 12 (+\u002F- 4) weeks prior to randomization.\n\n  * For patients receiving thoracic radiotherapy, the enrolling physician must confirm there are no computed tomography (CT) changes suggestive of fibrotic interstitial lung disease (ILD) (i.e., reticular changes, traction bronchiectasis, or honeycombing) reported on any prior CT scans. If any are present, the patient must be assessed by a respirologist to rule out ILD prior to enrollment.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry.\n\nShould a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* . Participants who have no option for standard systemic therapy or refuse systemic therapy.\n* Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.\n* Serious medical comorbidities precluding radiotherapy. These include ILD in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix E. All such cases must be discussed with the PI or Co-I .\n\n  * Malignant pleural effusion.\n* Inability to treat all sites of disease.\n\n  * Metastatic disease that invades any of the following: GI tract (including esophagus, stomach, small or large bowel) or skin.\n  * Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n  * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n  * Pregnant or nursing female participants.","1 Year",{"count":227,"type":21},800,[89],"This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers",[29,231,232,92],"Lung Cancer","Colo-rectal Cancer","2026-02-02",{"date":235,"type":41},"2026-02-04",{"date":237,"type":41},"2024-09-18",{"date":239,"type":21},"2032-09-18",{"name":241,"class":48},"Roswell Park Cancer Institute",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":252,"studyType":152,"phases":4,"briefSummary":253,"conditions":254,"keywords":259,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":49},"100602271","smc-radiation-oncology-sabr-cohort-for-oligometastasis-100602271","NCT07121335","SMC Radiation Oncology SABR Cohort for Oligometastasis","Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer","SABR-OMOP","Inclusion Criteria:\n\n* Performance status (ECOG PS) 0-2\n* Diagnosed with metastatic disease\n* Confirmed to have oligometastatic\u002Foligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)\n\nExclusion Criteria:\n\n* Patient with a history of prior radiotherapy to the site planned for SABR\n* Patients with concomitant brain metastases",{"count":251,"type":21},60,"3 Years","The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.\n\nThe main questions it aims to answer are:\n\n1. oncologic outcomes (progression-free survival, local failure rate),\n2. patient-reported outcomes,\n3. physician-assessed toxicity, and\n4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.",[255,29,256,257,258],"Stereotactic Body Radiation Therapy (SBRT)","Oligoprogression","ctDNA","Patient-Reported Outcomes (PRO)",[260,29,256,257],"Stereotactic body radiotherapy","2025-08-08",{"date":263,"type":41},"2025-08-13",{"date":265,"type":41},"2025-05-01",{"date":267,"type":21},"2030-03-31",{"name":269,"class":48},"Samsung Medical Center",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":277,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":49},"100565611","ablation-of-pulmonary-oligometastasis-combined-with-system-for-advanced-hepatocellular-carcinoma-100565611","NCT06644430","Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of pulmonary oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of first-line systemic therapy for minimum of 3 months before ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included;\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. intermediate HCC;\n2. age \\\u003C 18 years or \\> 75 years;\n3. advanced HCC with more than five metastases;\n4. no response to Lenvatinib;\n5. metastases size \\> 5 cm;\n6. life expectancy less than 3 months.",{"count":278,"type":21},470,"Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.",[281,231,29,282,283],"Advanced Hepatocellular Carcinoma","Ablation","Systemic Therapy",[285,286,287,288,289,290,291,292],"Advanced hepatocellular carcinoma","Lenvatinib","Sorafeinib","Camrelizumab","Tislelizumab","Sintilimab","Toripalimab","Apatinib","2024-12-01",{"date":295,"type":41},"2024-12-03",{"date":297,"type":41},"2024-10-04",{"date":299,"type":21},"2025-12-30",{"name":301,"class":48},"Sun Yat-sen University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":328,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":340},"100400786","stereotactic-body-radiotherapy-in-patients-with-rare-oligometastatic-cancers-oligorare-100400786","NCT04498767","Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial","OligoRARE","Inclusion Criteria:\n\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Controlled primary tumour, defined as:\n* at least 3 months since original tumour treated definitively, with no progression at primary site\n* Total number of oligometastases of 1-5 including:\n* Brain metastases amenable to radiosurgery or fractionated stereotactic radiotherapy patient who had neurosurgical resection before trial inclusion are allowed and resected brain metastases count to the total number of oligometastases\n* All sites of disease can be safely treated based on the judgement of an experienced radiation oncologist\n* ECOG score 0-2\n* Life expectancy \\> 6 months\n* Age 18 or older\n* Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Primary cancer of prostate, breast, lung or colorectal\n* Serious medical comorbidities precluding radiotherapy:\n* These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C)\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated previously with radiation, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in the RTQA Guidelines. All such cases should be discussed with one of the study coordinators\n* Brain metastases only, without extra-cerebral metastases\n* Malignant pleural effusion, malignant ascites, meningeal carcinomatosis and peritoneal carcinomatosis\n* Maximum size of 6 cm for lesions outside the brain, except:\n* Bone metastases over 5 cm may be included, if in the opinion of the local radiation oncologist it can be treated safely (e.g. rib, scapula, pelvis)\n* Clinical or radiologic evidence of symptomatic spinal cord compression. Patients can be eligible if surgical resection has been performed, but the surgical site counts toward the total of up to 3 metastases.\n* Metastatic disease that invades any of the following: GI tract (including oesophagus, stomach, small or large bowel), mesenteric lymph nodes, or disseminated skin metastases and lymphangiosis\n* Pregnant or breast feeding women\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial",{"count":311,"type":21},200,[24],"This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.\n\nPatients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease.\n\nThe primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.",[315,316,317,318,319,27,320,321,322,323,324,325,326,327,29],"Gynecologic Cancer","Skin Cancer","Head and Neck Cancer","Sarcoma","Renal Cancer","Upper Urinary Tract Carcinoma","Pancreatic Cancer","Hepatobiliary Cancer","Gastric Cancer","Small Bowel Cancer","Esophageal Cancer","Melanoma","Colon Cancer",[329,260,31],"oligometastatic cancer","2024-08-23",{"date":332,"type":41},"2024-08-26",{"date":334,"type":41},"2021-06-10",{"date":336,"type":21},"2030-02-01",{"name":338,"class":339},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",13,{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":49},"100558423","ablation-of-oligometastasis-combined-with-lenvatinib-and-pd-1-inhibitor-for-advanced-hepatocellular-carcinoma-100558423","NCT06550921","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Multicenter, Prospective, Phase II Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases 20;\n2. presence of oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy for a minimum of 3 months before study ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC);\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. advanced HCC Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;\n3. age \\\u003C 18 years or \\> 75 years;\n4. advanced HCC with more than five metastases;\n5. no response to Lenvatinib;\n6. metastases size \\> 5 cm;\n7. life expectancy less than 3 months.","75 Years",{"count":251,"type":21},[24],"Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.",[281,29,282,353,286],"Anti-PD1 Antibody",[355,289,290,288],"Lenvatinb","2024-08-08",{"date":358,"type":41},"2024-08-13",{"date":360,"type":41},"2024-08-01",{"date":362,"type":21},"2027-08-30",{"name":301,"class":48},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":380,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":49},"100466318","phase-3-metastasis-directed-therapy-for-oligorecurrent-prostate-cancer-100466318","NCT05352178","Metastasis-directed Therapy for Oligorecurrent Prostate Cancer","a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?","SPARKLE","Inclusion Criteria:\n\n* Histologically proven initial diagnosis of prostate adenocarcinoma\n* Priory treated and controlled primary tumor\n* Biochemical recurrence defined by prostate-specific antigen (PSA) values \\>0,2 ng\u002Fml (i.e., two consecutive increases) following radical prostatectomy + postoperative radiotherapy and a PSA value of 2 ng\u002Fml above the nadir after high-dose RT.\n* Oligorecurrent disease defined as a maximum of 5 extracranial metastases in any organ, diagnosed on PSMA PET-CT or PSMA PET-MRI reported according to the E-PSMA consensus guidelines for interpretation of PSMA-PET (26). Nodal (N1) disease can be included only when accompanied by M1a-c disease, provided that the total number of spots does not exceed 5.\n* Serum testosterone level within normal range.\n* WHO performance 0-2\n* Age \\>= 18 years old\n* Absence of psychological, sociological or geographical condition potentially hampering compliance with study protocol.\n* Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* 2\\. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.\n\nExclusion Criteria:\n\n* Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol\n* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial\n* Participation in an interventional Trial with an investigational medicinal product (IMP) or device\n* Serum testosterone level at castration level.\n* PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)\n* Presence of poly-metastatic disease, defined as more than 5 metastatic lesions.\n* Active malignancy other than prostate cancer that could potentially interfere with the interpretation of this trial.\n* Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.\n* Contra indications for intake of enzalutamide (seizure or any condition that may predispose to seizure; significant cardiovascular disease within the last three months including myocardial infarction, unstable angina, congestive heart failure, ongoing arrythmias of grade \\> 2 or a thromboembolic event).\n* Not able to understand the treatment protocol or sign informed consent.",{"count":373,"type":21},873,[89],"The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and\u002For metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.",[92,377,378,204,131,29,379],"Prostate Cancer Recurrent","Prostate Cancer Metastatic","Hormone Sensitive Prostate Cancer",[381,382,383,102],"Androgen deprivation therapy","Androgen receptor targeted agent","Stereotactic body radiation therapy","2024-07-01",{"date":386,"type":41},"2024-07-03",{"date":388,"type":41},"2022-04-20",{"date":390,"type":21},"2032-04-25",{"name":392,"class":48},"Universitaire Ziekenhuizen KU Leuven",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":176,"enrollmentInfo":400,"targetDuration":402,"studyType":152,"phases":4,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":421,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100549161","outcomes-of-local-treatment-for-oligometastatic-prostate-cancer-diagnosed-using-psma-pet-imaging-oligomet-study-100549161","NCT06430411","Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study","OLIGOMET","Inclusion Criteria:\n\n* Oligometastatic prostate cancer diagnosed using PSMA PET defined as cM1a and\u002For cM1b with ≤5 osseous metastases and\u002For M1c with ≤3 lung lesions, with or without cN positivity.\n* Oligometastatic prostate cancer treated with primary local therapy such as radical prostatectomy or radiation therapy.\n* Any Gleason Score, any cT stage, any PSA\n\nExclusion Criteria:\n\n* Visceral metastases (apart from lungs).\n* Neoadjuvant therapy prior to first PSMA PET.\n* Non-metastatic prostate cancer.\n* Patients who did not undergo imaging before local treatment.",{"count":401,"type":21},500,"5 Years","PSMA-PET\u002FCT or PSMA-PET\u002FMRI are more accurate imaging modalities compared to CT\u002FBS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease. Therefore a substantial proportion of high-risk patients previously considered as non-metastatic are expected to be diagnosed with oligometastatic disease. While standard treatment pathways exist for patients with non-metastatic or oligometastatic disease confirmed using conventional imaging, less is known about the optimal management of patients with oligometastatic prostate cancer on PSMA-PET.\n\nCurrently, data on the safety, effectiveness and oncologic outcomes of local therapies in oligometastatic patients diagnosed using PSMA-PET have been poorly reported so far. Thus, there is a need for a prospectively maintained database to collect real-world clinical data to produce high-quality research on the optimal management in oligometastatic prostate cancer who underwent PSMA-PET for primary staging and subsequent local therapy. This database will allow centers to retro- and prospectively collect data to facilitate analysis and assessment of the outcomes of oligometastatic patients managed with local therapy.",[378,405,92,406,131,29],"Prostate Cancer Metastatic to Bone","Prostate Neoplasm",[408,409,158,410,411,412,413,414,415,416,417,418,419,420],"prostate","oligometastatic","oligomet","prostatectomy","irradiation","abiraterone","enzalutamide","darolutamide","apalutamide","androgen deprivation therapy","ADT","docetaxel","PSMA PET","NOT_YET_RECRUITING","2024-05-24",{"date":424,"type":41},"2024-05-28",{"date":426,"type":21},"2024-05-31",{"date":428,"type":21},"2031-12-31",{"name":430,"class":48},"Medical University of Vienna",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":439,"minAge":18,"maxAge":348,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":453,"locationsCount":455},"100374698","radical-local-vs-palliative-therapy-for-breast-cancer-patientts-with-ipsilateral-humerus-or-sternum-oligometastasis-100374698","NCT04158843","Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis","A Randomized, Open Label Trial to Evaluate Radical Local Treatment Versus Palliative Treatment for Breast Cancer Patients With Ipsilateral Humerus or Sternum Oligometastasis","BOMB","Inclusion Criteria:\n\n* Patients provided written informed consent\n* Women aged 18-75 years old\n* Histologically confirmed breast cancer and after radical mastectomy\n* Patients of breast cancer with ipsilateral humerus or sternum oligometastasis, and there is no imaging evidence of other site metastases\n* Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade = 1 from any acute CTCAE v. 5.0 grade =2 side effects of previous treatments\n* Without infection of human immunodeficiency virus (HIV) on central laboratory assay results prior to randomization\n* Alanine aminotransferase (ALT) \\\u003C\u002F= 2.5 × the upper limit of normal (ULN), Aspartate aminotransferase (AST) \\\u003C\u002F= 2.5 × ULN prior to randomization\n* Total bilirubin (TBIL) \\\u003C\u002F= 1.25 × ULN\n* Alkaline phosphatase (ALK) \\\u003C\u002F= 2.5 × ULN\n* Gamma glutamyl transpeptidase (GGT) \\\u003C\u002F= 2.5 × ULN\n* Albumin \\>\u002F= 30g\u002FL\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2\n* Women of child-bearing age should take effective contraceptive measures\n* Serum total bilirubin (TBil) \\\u003C\u002F= 1.5 × ULN\n* Serum creatinine (Scr) \\\u003C\u002F= 1.5 × ULN\n* White blood cell count (WBC) \\>\u002F= 3×109\u002FL, Blood neutrophil count \\>\u002F= 1.5×109\u002FL, Platelet count \\>\u002F= 100×109\u002FL, Hemoglobin (HB) \\>\u002F= 9 g\u002FdL\n\nExclusion Criteria:\n\n* Without radical mastectomy of the primary breast lesions\n* No radical resection or radiotherapy is possible for metastatic lesions\n* Other site metastases except ipsilateral humerus or sternum are present\n* With multiple metastatic lesions\n* Any other current malignancy or malignancy diagnosed within the past five years (other than carcinoma in situ or stage Ia carcinoma of the cervix, skin basal cell carcinoma and papillary thyroid carcinoma at early stage)\n* Active infection with human immunodeficiency virus (HIV) prior to first study treatment administration.\n* History of participating any other clinical trials within 30 days prior to randomization\n* Known unable to tolerate humerus or sternal surgery or radical radiotherapy\n* Pregnancy or lactation\n* Current severe systemic disease (for example, clinically significant cardiovascular, pulmonary, or renal disease)\n* Legal incompetence or limitation.\n* Considered unable to complete the study or sign the informed consent due to a medical or mental disorder by the investigator.","FEMALE",{"count":441,"type":21},183,[24],"A Randomized, Open Label, Phase III Trial to Evaluate Radical Local Treatment versus Palliative Treatment for Breast Cancer Patients with Primary Ipsilateral Humerus or Sternum Oligometastasis",[155,29],[155,29,446,447],"Humerus","Sternum","2020-05-09",{"date":450,"type":41},"2020-05-12",{"date":448,"type":21},{"date":74,"type":21},{"name":454,"class":48},"xuexin he",4,{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":465,"briefSummary":466,"conditions":467,"keywords":470,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":49},"100375764","feasibility-of-online-mr-guided-radiotherapy-on-a-15t-mr-linac-100375764","NCT04172753","Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac","Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)","Inclusion Criteria:\n\n* existing indication for radiation therapy\n* minimum age 18 years, no upper age limit\n* capacity for consent\n* Informed consent\n\nExclusion Criteria:\n\n* contraindication for MRI (claustrophobia, metallic implants not applicable for MRI\n* pregnancy",{"count":464,"type":21},472,[24],"This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.",[468,317,469,155,92,29,325],"Rectal Cancer","Liver Cancer",[471,472],"Radiotherapy","Adaptive Radiotherapy","2019-11-19",{"date":475,"type":41},"2019-11-21",{"date":477,"type":41},"2018-05-09",{"date":479,"type":21},"2027-05-09",{"name":481,"class":48},"University Hospital Tuebingen"]